Benitec Biopharma Inc banner

Benitec Biopharma Inc
XBER:BJ9

Watchlist Manager
Benitec Biopharma Inc Logo
Benitec Biopharma Inc
XBER:BJ9
Watchlist
Price: 0.0115 EUR Market Closed
Market Cap: €18.9k

Wall St Price Targets

BJ9 Price Targets Summary
Benitec Biopharma Inc

Wall Street analysts forecast BJ9 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BJ9 is 0.0239 EUR with a low forecast of 0.0166 EUR and a high forecast of 0.0307 EUR.

Lowest Forecast
Price Target
0.0166 EUR
45% Upside
Average Forecast
Price Target
0.0239 EUR
108% Upside
Highest Forecast
Price Target
0.0307 EUR
167% Upside
Benitec Biopharma Inc Competitors:
Price Targets
PRQR
ProQR Therapeutics NV
434% Upside
FULT
Fulton Financial Corp
9% Upside
ZNTL
Zentalis Pharmaceuticals Inc
53% Upside
UFPT
UFP Technologies Inc
52% Upside
AYTU
Aytu Biopharma Inc
272% Upside
AMSF
Amerisafe Inc
29% Upside

Revenue
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-88%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-88%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is BJ9's stock price target?
Price Target
0.0239 EUR

According to Wall Street analysts, the average 1-year price target for BJ9 is 0.0239 EUR with a low forecast of 0.0166 EUR and a high forecast of 0.0307 EUR.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett